# Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

> **NCT07521332** · PHASE4 · RECRUITING · sponsor: **Asian Institute Of Medical Sciences** · enrollment: 220 (estimated)

## Conditions studied

- Cirrhosis
- Esophageal and Gastric Varices
- Ascites
- Hepatic Encephalopathy
- Portal Vein Thrombosis
- Portal Hypertension

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Carvedilol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07521332
- **Lead sponsor:** Asian Institute Of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521332, "Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07521332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*